MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Sarepta Therapeutics ROE Ratio 2011-2026 | SRPT
Annual ROE Ratio Sarepta Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -36.14 | 10.41 | -62.37 | -182.75 | -45.13 | -72.74 | -87.4 | -35.06 | -6.42 | -79.38 | -115.59 | -54.83 | -45.3 | -98.07 | -7.47 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.41 | -182.75 | -61.22 |
Quarterly ROE Ratio Sarepta Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -35.53 | -19.15 | -33.06 | 7.11 | 1.75 | -6.35 | -10.18 | -81.09 | -140.91 | -195.38 | -224.01 | -103.94 | -114.2 | -64.63 | -49.54 | -58.27 | -83.12 | -98.66 | -101.68 | -72.74 | -76.7 | -66.34 | -80.33 | -87.4 | -72.24 | -64.2 | -41.0 | -35.06 | -24.45 | -23.1 | -20.5 | -6.42 | -29.65 | -40.46 | -50.97 | -79.38 | -87.09 | -97.52 | -101.01 | -115.59 | -99.55 | -84.06 | -75.75 | -54.83 | -40.46 | -45.67 | -39.69 | -45.3 | -91.92 | -114.98 | -100.78 | -98.07 | -52.43 | -25.32 | -27.7 | -7.47 | -12.96 | 4.12 | 5.91 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.11 | -224.01 | -62.54 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
-43.75 | $ 4.5 | 0.45 % | $ 862 M |  Canada |
 |
ADC Therapeutics SA
ADCT
|
-138.5 | $ 3.83 | 1.32 % | $ 105 M |  Schweiz |
 |
Agenus
AGEN
|
1.14 | $ 3.64 | 9.31 % | $ 108 M |  USA |
 |
Agios Pharmaceuticals
AGIO
|
-34.6 | $ 35.08 | -0.36 % | $ 2.03 B | USA |
 |
Akebia Therapeutics
AKBA
|
-16.39 | $ 1.39 | 0.36 % | $ 357 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-61.06 | $ 3.95 | -11.63 % | $ 266 B |  Britain |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Aldeyra Therapeutics
ALDX
|
-76.49 | $ 1.57 | -5.42 % | $ 94.3 M | USA |
 |
Aligos Therapeutics
ALGS
|
-45.18 | $ 8.08 | 1.38 % | $ 79.9 M | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
Alnylam Pharmaceuticals
ALNY
|
39.76 | $ 331.14 | 3.85 % | $ 43.4 B | USA |
 |
Altimmune
ALT
|
-39.17 | $ 3.4 | 1.8 % | $ 300 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-391.42 | $ 1.99 | 0.81 % | $ 107 M | USA |
 |
Amgen
AMGN
|
89.06 | $ 344.03 | -1.12 % | $ 185 B | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
-101.78 | $ 12.27 | -1.68 % | $ 3.85 B | USA |
 |
Anika Therapeutics
ANIK
|
-38.95 | $ 14.99 | 1.28 % | $ 220 M | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
-4.59 | $ 73.8 | -0.55 % | $ 1.43 B | USA |
 |
Annexon
ANNX
|
-97.66 | $ 5.56 | 1.0 % | $ 862 M | USA |
 |
Annovis Bio
ANVS
|
-171.23 | $ 2.56 | 12.28 % | $ 52.6 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Aptorum Group Limited
APM
|
-20.19 | $ 0.88 | -5.16 % | $ 4.8 M | China |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Aprea Therapeutics
APRE
|
-101.27 | $ 0.7 | -1.87 % | $ 4.58 M | USA |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 4.12 | -0.24 % | $ 441 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-30.74 | $ 8.14 | 1.31 % | $ 223 M |  Israel |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Ardelyx
ARDX
|
-36.9 | $ 5.99 | 0.84 % | $ 1.44 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 24.06 | 1.82 % | $ 3.06 B | USA |
 |
Arvinas
ARVN
|
-18.62 | $ 10.87 | 0.14 % | $ 771 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
-0.35 | $ 60.28 | -1.23 % | $ 8.06 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M | USA |
 |
Assembly Biosciences
ASMB
|
-2.96 | $ 29.51 | 1.72 % | $ 331 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-294.78 | - | 10.36 % | $ 9.8 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-36.22 | $ 3.62 | 1.82 % | $ 8.71 B |  Australia |